

Screening for colon cancer with Cologuard[®]

A step in the
right direction



 **cologuard[®]**
Rx only

Cologuard is intended to screen adults 45 and older at average risk for colorectal cancer. Rx only.

Please see important risk information on back of brochure.



Taking **care** of yourself by screening for colorectal cancer

It is the most preventable form of cancer¹

It's on the rise in people 45-49²

When caught in early stages, it's more treatable in 90% of people*³

That's why timely screening should be part of your regular health check-ups

*Based on 5-year survival.

Cologuard finds colon cancer even in early stages^{4,5}



Cologuard is a noninvasive screening option. There's no prep and you can screen in the privacy of your home.



Cologuard finds 92% of cancers overall⁴



Cologuard finds 94% of Stage I & II cancers⁵



I'm easy to use!


Scan to watch the How to Use video, or visit CologuardTest.com/use

Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. In this clinical study, 13% of patients received false positive results and 8% received false negative results.

Please see important risk information on back of brochure.



Most insured
patients
pay \$0*



Cologuard is covered by Medicare and most major insurers

Nationwide, more than 94%
of Cologuard patients have no
out-of-pocket cost for
screening.*



Want to know more
about insurance coverage? Go to
CologuardTest.com/insurance

*Rate of coverage varies by state and region.
Coverage rate only applies to Cologuard
screening population.

Don't wait

Ask your healthcare provider
about Cologuard today

For more info, call
1-844-870-8870 or visit
CologuardTest.com



Cologuard is intended to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use if you have had adenomas, have inflammatory bowel disease and certain hereditary syndromes, or a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older.

The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for diagnostic colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. False positives and false negative results can occur. In a clinical study, 13% of people without cancer received a positive result (false positive) and 8% of people with cancer received a negative result (false negative). Rx only.

REFERENCES

1. Itzkowitz SH. Incremental advances in excremental cancer detection tests. *J Natl Cancer Inst.* 2009;101(18):1225-1227.
2. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin.* 2018;68(4):250-281.
3. National Cancer Institute. SEER cancer stat facts: colorectal cancer. <https://seer.cancer.gov/statfacts/html/correct.html>. Accessed February 4, 2020.
4. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med.* 2014;370(14):1287-1297.
5. Ahlquist DA. Multi-target stool DNA test: a new high bar for noninvasive screening. *Dig Dis Sci.* 2015;60(3):623-633.

**EXACT
SCIENCES**

 **cologuard**[®]
Rx only

EXACT SCIENCES CORPORATION 441 Charmany Drive, Madison, WI 53719
www.ExactSciences.com | www.ExactLabs.com | 1-844-870-8870

Cologuard is a registered trademark of Exact Sciences Corporation.
©2020 Exact Sciences Corporation. All rights reserved. US.CG.2859-1-February 2020.